Key result
Cilostazol was more effective than pentoxifylline in increasing intermittent and absolute claudication distances and ankle brachial index in patients with peripheral arterial disease.
Why the study?
Does cilostazol improve claudication distances and ankle brachial index more than pentoxifylline in patients with occlusive peripheral arterial disease?
RCT (n=70)
1:1 ratio using a computer-generated random allocation sequence
No
Does cilostazol improve claudication distances and ankle brachial index more than pentoxifylline in patients with occlusive peripheral arterial disease?
Cilostazol is more effective than pentoxifylline at improving functional walking distances and ankle brachial index in patients with peripheral arterial disease.
Answers are grounded in this paper and cite their sources.
Supports preferring cilostazol over pentoxifylline for claudication in PAD; reinforces larger RCTs.
Aims: A comparative study of Cilostazole and Pentoxifylline on intermittent claudication in patients of peripheral arterial disease. Materials and Methods: A total of 70 patients clinically proven occlusive peripheral arterial disease admitted at wards of General Surgery at Acharya Vinoba Bhave Rural Hospital, Sawangi, Wardha. It was prospective study the patients were randomized in two groups in 1:1 ratio. The randomization was done using a random allocation sequence generated by computer program and sequential patient consenting to participate in the study was allocated in the respective treatment arms - Cilostazole and Pentoxyphylline per the allocation sequence. Group I Patients (n=35) were administered Tab. Pentoxifylline 400 mg thrice a day; Group II (n=35), Tab Cilostazol 100 mg twice a day. History, clinical examination, all routine investigation including lipid profile, color Doppler study of lower limb and Angiography of lower limb vessels was performed at the start of the trial. Patients were re-evaluated at the time of enrolment and at 24 weeks for Intermittent Claudication Distance (ICD), Absolute Claudication Distance (ACD), and Ankle Brachial Index (ABI). Results: The group II (Cilostazole Group) showed more rise in intermittent claudication distance and Acute Claudication Distance as compared to Pentoxifylline. There was also statically improvement in ankle brachial index of Group II (Cilostazole Group) as compared to Group I (Pentoxifylline). Conclusion: Thus, the comparative analysis revealed that the efficacy of Cilostazole is more than the Pentoxifylline in increasing the ICD and ACD in patients of occlusive peripheral arterial disease with stable intermittent claudication in patients of peripheral arterial disease.
No takes yet. Share an insight, caveat, or question.
Mahakalkar et al. (2017) conducted an RCT in Intermittent claudication in peripheral arterial disease (n=70). Cilostazol vs. Pentoxifylline 400 mg thrice a day was evaluated on Intermittent Claudication Distance (ICD), Absolute Claudication Distance (ACD), and Ankle Brachial Index (ABI). Cilostazol was more effective than pentoxifylline in increasing intermittent and absolute claudication distances and ankle brachial index in patients with peripheral arterial disease.
Synapse has enriched 10 related papers. Consider them for comparative context: